心科科学公司 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 HEARTSCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ Accelerated filer☐Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of September 10, 2025, the registrant had2,647,712shares of Common Stock outstanding. HEARTSCIENCES INC. NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of theSecurities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended(the “Exchange Act”). These forward-looking statements relate to our future plans, objectives, expectations and intentions and maybe identified by terminology such as “may,” “will,” “should,” “expects,” “aims,” “plans,” “anticipates,” “believes,” “estimates,”“predicts,” “potential,” “intends,” or “continue,” or the negative of these terms or other comparable terminology. Readers arecautioned that these forward-looking statements are based on our current beliefs, expectations and assumptions and are subject torisks, uncertainties, and assumptions that are difficult to predict, including those identified below, under Part II, Item 1A “RiskFactors” and elsewhere in this Quarterly Report on Form 10-Q and those risks identified under Part I, Item 1A of our AnnualReport on Form 10-K for the year ended April 30, 2025 filed with the Securities and Exchange Commission on July 24, 2025("2025 Annual Report on Form 10-K"). Therefore, actual results may differ materially and adversely from those expressed,projected or implied in any forward-looking statements. We undertake no obligation to revise or update any forward-lookingstatements for any reason. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans andstrategies, statements that contain projections of results of operations or of financial condition, expected capital needs andexpenses, statements relating to the research, development, completion and use of our device, and all statements (other thanstatements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipatewill or may occur in the future. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. We havebased these forward-looking statements on assumptions and assessments made by our management in light of their experience andtheir perception of historical trends, current conditions, expected future developments and other factors they believe to beappropriate. Important factors that could cause actual results, developments and business decisions to differ materially from thoseanticipated in these forward-looking statements include, among other things: •our expectation regarding the sufficiency of our existing cash and cash equivalents to fund our current operations;•our ability to receive regulatory clearance for the MyoVistawavECG or the MyoVista Insights Cloud Platform andassociated AI-ECG algorithms from the U.S. Food and Drug Administration (the “FDA”), state regulators, if any, orother similar foreign regulatory agencies, including approval to conduct clinical trials, the timing and scope of thosetrials and the prospects for regulatory approval or clearance of, or other regulatory action with respect to